Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Niacin Stories

2009-12-10 10:00:00

ABBOTT PARK, Ill., Dec. 10 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR®, a cholesterol medication. SIMCOR is a fixed-dose combination of niacin extended-release and simvastatin. Abbott is seeking FDA approval for the following new dosage strengths of SIMCOR: 500/40 mg and 1000/40 mg (niacin extended-release/simvastatin)....

2009-11-20 21:05:00

BEVERLY HILLS, Calif., Nov. 20 /PRNewswire/ -- In the study presented today at the American Heart Association Scientific Sessions in Orlando, Florida today, The Effect of Extended-release Niacin or Ezetimibe Added to Chronic Statin Therapy On Carotid Intima Media Thickness (ARBITER 6-HALTS), study found that: Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8...

2009-11-18 14:50:57

Blood cholesterol levels improved, but arteries do not show it The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. In tests on 145 Baltimore-area men and women with existing atherosclerosis,...

2009-11-16 13:50:01

Statin therapy should still be used first to reach blood cholesterol levels before considering addition of niacin Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible...

eebf2d573f8d968dfcc8c033d5fd7db11
2009-11-16 12:46:29

A new study has exposed weaknesses on the part of cholesterol-lowering drugs Zetia and Vytorin. In a recent study consisting of 208 patients, scientists looked at the primary ingredient of Zetia and Vytorin, called ezetimibe. They compared the ingredient to a B-vitamin known as niacin, which is available for much less than either prescription pill. Researchers found that patients that were given ezetimibe had lower levels of LDL cholesterol, while those who received niacin had less blockage...

2009-11-16 11:36:00

MAPLE GROVE, Minn., Nov. 16 /PRNewswire/ -- Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. The objective was to study the lipid and anti-inflammatory effects of Slo-Niacin® 1.5 g/day and Lipitor (atorvastatin calcium) 10 mg/day, given alone and then together in persons with features of combined...

2009-11-15 20:07:00

Study highlights: In patients with or at high-risk for coronary artery disease and LDL (bad cholesterol) treated with statins to < 100mg/dL but low HDL (good cholesterol), adding medication to raise HDL was compared with lowering LDL further. Patients were randomized to the addition of niacin (primarily to raise HDL), or ezetimibe (to further lower LDL cholesterol). Plaque buildup in the lining of the neck arteries was significantly reduced only in the niacin group. DUE TO AN EMBARGO...

2009-11-15 17:28:00

ORLANDO, Fla., Nov. 15 /PRNewswire-FirstCall/ -- Results from the investigator-initiated ARBITER 6 - HALTS study showed patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and 14 months of therapy with Abbott's Niaspan® (niacin extended-release tablets) plus a statin, the study's primary endpoint. In a pre-specified secondary endpoint of the study, treatment with Niaspan plus statin also resulted in significantly fewer major adverse...

2009-07-22 12:08:00

Food Storage Safety: Tips to Avoid Food Poisoning ROCHESTER, Minn., July 22 /PRNewswire-USNewswire/ -- Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required. Reprinting is allowed for a fee. Include the following subscription information as your editorial policies permit: Visit www.bookstore.mayoclinic.com or call toll-free for subscription information,...

2009-06-25 08:00:00

ACUROX(R) and EMBEDA (TM) Data Highlighted at the College on Problems of Drug Dependence Annual Meeting RENO, Nev., June 25 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) today announced that the Company is presenting safety and efficacy data for ACUROX(R) and EMBEDA(TM) (ALO-01), two novel opioid analgesic formulations that are in development, at the 71st Annual Meeting of the College on Problems of Drug Dependence. King is also developing other pain medicines employing unique...